David Anselm
Analyst
Piper Sandler
Equibles does not estimate personal net worth.
About David Anselm
David Anselm is recorded as Analyst at Piper Sandler. David Anselm has spoken on 14 earnings calls across 11 companies, most recently for Pelthos Therapeutics Inc. on November 12, 2026. Those appearances were for Jazz Pharmaceuticals plc (JAZZ), Corcept Therapeutics Inc (CORT), Amneal Pharmaceuticals, Inc. (AMRX), Pelthos Therapeutics Inc. (PTHS), AMGEN-T and 6 other companies. The companies whose calls David Anselm spoke on are classified in the Healthcare sector.
David Anselm on recent calls
“I know you can't say all that much just yet on the transaction, but... Nonetheless, I wanted to get your thoughts on how you see DeFi's points of differentiation versus Vayjuvic.”
“On the phase three, are you going to explore a broader cutaneous lupus population, or will it be specific to discoid lupus? That's number one.”
“On the phase three, are you going to explore a broader cutaneous lupus population, or will it be specific to discoid lupus? That's number one.”
“How would you articulate your top business development slash M&A priorities as we move through 2027? I think, Kyle, early this year, you talked about being over-indexed in psychiatry.”
“So, I wanted to ask a commercialization question on lidofilumab, and I realize I might be putting the cart before the horse here given the data readouts, but I wanted to get your thoughts on how you're sizing the CLE opportunity relative to the SLE opportunity, bearing in mind that many patients with cutaneous disease…”
Affiliation history
-
Piper Sandler
Analyst
Transcript header (unverified)
Current
Company network
Drug Manufacturers - Specialty & Generic · Healthcare
AMGN
Drug Manufacturers - General · Healthcare
AMGEN-T
Drug Manufacturers - Specialty & Generic · Healthcare
BIIB
Drug Manufacturers - General · Healthcare
ABBV
Drug Manufacturers - General · Healthcare
Recent activity
-
-
-
Earnings call
Amgen Q3 2026 Earnings Conference Call
AMGEN-T
-
-
-
-
-
-
-
-
-